8-KMaterial AgreementsCorporate ChangesOther Events+1

BRISTOL MYERS SQUIBB CO 8-K Report, Material Agreement (Jun 16, 2005)

Filed June 16, 2005For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) has filed an 8-K report detailing significant corporate governance changes and the resolution of a legal investigation. The company's Board of Directors has separated the roles of Chairman of the Board and Chief Executive Officer, appointing James D. Robinson III as non-executive Chairman. This change involves specific compensation arrangements for Mr. Robinson, including annual retainers, meeting fees, and equity awards. Concurrently, BMY announced a Deferred Prosecution Agreement with the United States Attorney's Office (USAO) for the District of New Jersey to resolve investigations into wholesaler inventory and accounting matters. This agreement entails a substantial additional payment to a shareholder fund and the recording of an additional reserve, with a commitment to future compliance overseen by an independent monitor.

Key Highlights

  • 1Separation of Chairman and CEO roles with James D. Robinson III appointed non-executive Chairman.
  • 2James D. Robinson III to receive an annual retainer of $360,000 plus director fees and a one-time award of 40,000 restricted stock units.
  • 3BMY entered into a Deferred Prosecution Agreement with the U.S. Attorney's Office to resolve investigations.
  • 4BMY will make an additional $300 million payment to a shareholder fund.
  • 5An additional reserve of $249 million will be recorded in the second quarter of 2005.
  • 6An independent Monitor will oversee the company's compliance with the agreement.
  • 7BMY's Bylaws were amended to clarify the roles of Chairman and CEO.

Frequently Asked Questions

Separating these roles, with James D. Robinson III appointed as non-executive Chairman, is a corporate governance change aimed at enhancing oversight and accountability. It typically signifies a move towards independent leadership at the board level, distinct from day-to-day operational management.

The agreement requires Bristol-Myers Squibb to make an additional payment of $300 million to a shareholder fund and to record an additional reserve of $249 million in the second quarter of 2005. These represent significant financial commitments stemming from the resolution of the investigation.

The Honorable Frederick B. Lacey will serve as an independent Monitor through at least April 2007. His role is to oversee the company's compliance with all terms of the Deferred Prosecution Agreement, providing an independent assurance mechanism for regulators and stakeholders.

Mr. Robinson will receive an annual retainer of $360,000, in addition to his regular director retainer of $45,000. He will also receive $2,000 for attending each Board meeting and the Annual Meeting of Stockholders. Furthermore, he was granted 40,000 restricted stock units and receives other benefits typical for independent directors.